

Supplementary Table 2. Association between HbA1c level at the time of diagnosis and advanced fibrosis (fibrosis stage 3–4) in patients not using pioglitazone, glucagon-like peptide-1 receptor agonist, or sodium-glucose transport protein 2 inhibitor

Variable	HbA1c			
	≤5.4% (<i>n</i> =41)	5.5%–6.4% (<i>n</i> =140)	6.5%–7.4% (<i>n</i> =58)	≥7.5% (<i>n</i> =66)
Crude OR (95% CI)	1.00	2.78 (1.21–7.25) <i>P</i> =0.02	6.41 (2.55–17.96) <i>P</i> <0.01	4.05 (1.64–11.13) <i>P</i> <0.01
Adjusted OR (95% CI)				
Model 1	1.00	1.47 (0.55–3.93) <i>P</i> =0.43	2.88 (1.00–8.33) <i>P</i> =0.04	2.35 (0.84–6.59) <i>P</i> =0.10
Model 2	1.00	2.84 (1.12–7.18) <i>P</i> =0.02	5.66 (2.04–15.68) <i>P</i> <0.01	3.05 (1.09–8.56) <i>P</i> =0.03

Differences were considered statistically significant at *P*<0.05. Model 1 was adjusted for age (years), sex, and hemoglobin (g/L), alanine aminotransferase (IU/L), and creatinine (μmol/L) levels. Model 2 was adjusted for body mass index (kg/m²) and uric acid (μmol/L), total cholesterol (mmol/L), and triglyceride (mmol/L) levels.

HbA1c, glycosylated hemoglobin; OR, odds ratio; CI, confidence interval.